Cryoprecipitate-reduced plasma: Rationale for use and efficacy in the treatment of thrombotic thrombocytopenic purpura

Transfusion

Volumn 41, Issue 6, 2001, Pages 840-844

  Blackall, Douglas P ^a,b,c   Uhl, Lynne ^a,b,c   Spitalnik, Steven L ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; CRYOPRECIPITATE; DISEASE COURSE; GENETIC PREDISPOSITION; HUMAN; MICROANGIOPATHY; PATHOGENESIS; PLASMA TRANSFUSION; RELAPSE; SALVAGE THERAPY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VASCULAR DISEASE;

CRYOPRESERVATION; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 0034977878     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41060840.x     Document Type: Article

References (45)

1. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura
2. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura
3. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura
4. Refractory thrombotic thrombocytopenic purpura: Successful treatment by plasmapheresis with plasma cryosupernatant
5. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura
6. Cryoprecipitate-poor plasma fraction (cryosupernatant) in the treatment of thrombotic thrombocytopenic purpura at onset. A report of four cases
7. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: An undescribed disease
8. The thrombocytopenic purpuras: Recognition and management
9. Increasing mortality from thrombotic thrombocytopenic purpura in the United States- analysis of national mortality data, 1968-1991
10. Treatment of thrombotic thrombocytopenic purpura. Evaluation of plasma exchange and review of the literature
11. Efficacy of intensive plasmapheresis in thrombotic thrombocytopenic purpura
12. Thrombotic thrombocytopenic purpura: Treatment with plasmapheresis
13. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients
14. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
15. The pathophysiology and management of thrombotic thrombocytopenic purpura
16. Thrombotic thrombocytopenic purpura
17. Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients
18. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
19. Abnormal VIII:Von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndrome
20. Von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura
21. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura
22. Abnormal platelet von Willebrand factor interaction in patients with TTP
23. Thrombotic thrombocytopenic purpura: Successful treatment unlocks etiologic secrets
24. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
25. The role of von Willebrand factor (vWF) in thrombotic thrombocytopenic purpura (TTP) and the hemolytic-uremic syndrome (HUS)
26. The platelet aggregating factor(s) of thrombotic thrombocytopenic purpura
27. Efficacy of several plasma components in a young boy with chronic thrombocytopenia and hemolytic anemia who responds repeatedly to normal plasma infusions
28. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families
29. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa
30. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
31. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
32. Treatment of thrombotic thrombocytopenic purpura with plasma
33. Studies of a patient with recurring thrombotic thrombocytopenic purpura
34. Thrombotic thrombocytopenic purpura: Recovery after splenectomy associated with persistence of abnormally large von Willebrand factor multimers
35. Management of treatment failures in thrombotic thrombocytopenic purpura
36. Recovery by splenectomy in patients with relapsed thrombotic thrombocytopenic purpura and treatment failure to plasma exchange
37. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoadsorption
38. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian cooperative group for TTP
39. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura
40. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
41. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura
42. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura
43. S/D plasma in TTP and coagulation factor deficiencies for which no concentrates are available
44. FDA liaison committee meets with FDA representatives